You are here: Industry Insights > Apellis

News List

Apellis, Beam ink base-editing pact to tackle complement-driven diseases firstwordpharma
July 01, 2021
Apellis Pharmaceuticals and Beam Therapeutics have forged a five-year research partnership that will apply the latter's base-editing platform toward discovering new treatments for complement-driven diseases, the companies announced Wednesday.
Apellis Will Not Peruse Development of APL-9 for Severe COVID-19 americanpharmaceuticalreview
March 10, 2021
Apellis Pharmaceuticals announced the company will not pursue additional development of APL-9, an investigational targeted C3 therapy designed for acute interventions, for the treatment of severe COVID-19.
Apellis enters drug development and commercialisation deal with Sobi pharmaceutical-technology
October 29, 2020
Apellis Pharmaceuticals has entered into a strategic collaboration with Swedish Orphan Biovitrum (Sobi) to fast-track the advancement of systemic pegcetacoplan to treat multiple rare diseases with high unmet need.
Apellis to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria americanpharmaceuticalreview
May 27, 2020
Apellis Pharmaceuticals announced plans to submit a New Drug Application (NDA) for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the second half of 2020.
Enable Injections Partners with UCB and Apellis Pharmaceuticals contractpharma
November 14, 2018
Enable Injections Partners with UCB and Apellis Pharmaceuticals
Apellis sets up another phase 3 program for lead drug APL-2 fiercebiotech
August 28, 2017
Trials in dry age-related macular degeneration expand Apellis Pharmaceuticals' focus beyond rare diseases.